These results are consistent with the hypothesis that miR-675, derived from Oncofetal lncRNA-H19, reflects tumor dynamics more accurately than lncRNA-H19 and may therefore represent a new biomarker for the diagnosis, prognosis, and monitoring of therapeutic responses in HCC. The gene discussed is H19; the disease is neoplasm.